Biological Assembly 1  

 3D View: Structure | 1D-3D View | Electron Density | Validation Report | Ligand Interaction

Global Symmetry: Asymmetric - C1 
Global Stoichiometry: Monomer - A1 

Biological assembly 1 assigned by authors and generated by PISA (software)

Macromolecule Content

• Total Structure Weight: 43.01 kDa 
• Atom Count: 2906 
• Modelled Residue Count: 340 
• Deposited Residue Count: 371 
• Unique protein chains: 1

4EYM

MAPK13 complex with inhibitor

• PDB DOI: 10.2210/pdb4EYM/pdb

• Classification: Transferase/Transferase Inhibitor
• Organism(s): Homo sapiens
• Expression System: Escherichia coli
• Mutation(s): No 


• Deposited: 2012-05-01 Released: 2012-12-19 
• Deposition Author(s): Miller, C.A., Brett, T.J.

---

Experimental Data Snapshot

• Method: X-RAY DIFFRACTION
• Resolution: 2.35 Å
• R-Value Free: 0.269 
• R-Value Work: 0.203 
• R-Value Observed: 0.206 

Literature

IL-13-induced airway mucus production is attenuated by MAPK13 inhibition.

Alevy, Y.G., Patel, A.C., Romero, A.G., Patel, D.A., Tucker, J., Roswit, W.T., Miller, C.A., Heier, R.F., Byers, D.E., Brett, T.J., Holtzman, M.J.

(2012) J Clin Invest 122: 4555-4568

• PubMed: 23187130 
• DOI: 10.1172/JCI64896
• Primary Citation of Related Structures:  
  4EYJ, 4EYM, 4YNO


• PubMed Abstract: 
  

Increased mucus production is a common cause of morbidity and mortality in inflammatory airway diseases, including asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis. However, the precise molecular mechanisms for pathogenic mucus production are largely undetermined. Accordingly, there are no specific and effective anti-mucus therapeutics. Here, we define a signaling pathway from chloride channel calcium-activated 1 (CLCA1) to MAPK13 that is responsible for IL-13-driven mucus production in human airway epithelial cells. The same pathway was also highly activated in the lungs of humans with excess mucus production due to COPD. We further validated the pathway by using structure-based drug design to develop a series of novel MAPK13 inhibitors with nanomolar potency that effectively reduced mucus production in human airway epithelial cells. These results uncover and validate a new pathway for regulating mucus production as well as a corresponding therapeutic approach to mucus overproduction in inflammatory airway diseases.

---

Organizational Affiliation: 

Drug Discovery Program, Pulmonary and Critical Care Medicine, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri 63110, USA.

Macromolecules

Entity ID: 1
Molecule	Chains	Sequence Length	Organism	Details	Image
Mitogen-activated protein kinase 13	A	371	Homo sapiens	Mutation(s): 0  Gene Names: MAPK13, PRKM13, SAPK4 EC: 2.7.11.24
UniProt & NIH Common Fund Data Resources
Find proteins for O15264 (Homo sapiens) Explore O15264  Go to UniProtKB:  O15264
PHAROS:  O15264 GTEx:  ENSG00000156711

Small Molecules

Ligands 1 Unique
ID	Chains	Name / Formula / InChI Key	2D Diagram
0RX	B [auth A]	2-(morpholin-4-yl)-N-[4-(pyridin-4-yloxy)phenyl]pyridine-4-carboxamide C21 H20 N4 O3 DLOAYIHJIDPKJJ-UHFFFAOYSA-N

Binding Affinity Annotations
ID	Source	Binding Affinity
0RX	BindingDB:  4EYM	IC50: min: 1.49e+4, max: 9.87e+4 (nM) from 2 assay(s)
	PDBBind:  4EYM	IC50: 9.87e+4 (nM) from 1 assay(s)

Experimental Data & Validation

Experimental Data

• Method: X-RAY DIFFRACTION
• Resolution: 2.35 Å
• R-Value Free: 0.269 
• R-Value Work: 0.203 
• R-Value Observed: 0.206 
• Space Group: P 2₁ 2₁ 2₁
• Diffraction Data DOI: 10.15785/SBGRID/89 SBGrid

Unit Cell:

Length ( Å )	Angle ( ˚ )
a = 61.11	α = 90
b = 69.564	β = 90
c = 93.157	γ = 90

Software Package:

Software Name	Purpose
Blu-Ice	data collection
PHENIX	model building
PHENIX	refinement
HKL-2000	data reduction
SCALEPACK	data scaling
PHENIX	phasing

Structure Validation

Entry History 

Deposition Data

• Deposited Date: 2012-05-01 
• Released Date: 2012-12-19 
Deposition Author(s): Miller, C.A., Brett, T.J.

Revision History  

• Version 1.0: 2012-12-19
  Type: Initial release